trending Market Intelligence /marketintelligence/en/news-insights/trending/bs07oxgvz7k9tieoqzglda2 content esgSubNav
In This List

Regenxbio closes common stock offering

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Regenxbio closes common stock offering

Regenxbio Inc. closed an underwritten public offering of 2,700,000 common shares, priced $65 each.

The Rockville, Md.-based developer of gene therapies raised gross proceeds of about $201.8 million.

Underwriters fully exercised their option to buy 405,000 additional shares at the offering price.

Morgan Stanley, Bank of America Merrill Lynch and Barclays acted as joint book-running managers for the offering, with Raymond James as co-manager.